Potential Promising Therapy for Systemic AA Amyloidosis disease

 

Systebryl^™ is our lead compound currently in late pre-clinical stage of development to address the unmet therapeutic need of patients suffering from a rare disease known as Systemic AA Amyloidosis.  This disease impacts approximately 100,000 people in the United States alone every year.

 

To date, there is no approved FDA for the treatment of this disease.  Systebryl^™ has shown great promise in lab testing and in vivo modeling.  Lab research tests show that Systebryl^™ has a positive effect in preventing and/or reducing AA amyloid fibril formation associated with Systemic AA Amyloidosis.

 

ProteoTech will continue to develop Systebryl^™ and request Orphan Drug Status from the FDA with will provide extended patent protection due to smaller population of people afflicted with this disease.